COAGADEX
The FDA updated the indications for COAGADEX, a Factor X concentrate, for use in adult and pediatric patients with hereditary Factor X deficiency. The updated scope covers routine prophylaxis, on-demand treatment of bleeding episodes, and perioperative management for patients with mild to moderate deficiency.
The manufacturer (BPL), healthcare providers treating hereditary bleeding disorders, and regulatory/clinical departments responsible for biologics indicated for rare coagulation deficiencies.
The inclusion of routine prophylaxis and pediatric populations represents a significant therapeutic scope. Regulatory teams should observe this as a formalization of the clinical utility of the product across a broader patient demographic and surgical environment. This documentation likely reflects the culmination of clinical data supporting the transition from on-demand treatment to preventative maintenance in rare factor deficiencies.
Regulatory and clinical teams should ensure all labeling, promotional materials, and clinical protocols for Factor X therapies align with these specific prophylaxis and perioperative indications. Quality and safety teams should monitor for adverse events specifically within the pediatric and adult populations defined in the updated scope.
•Indicated in adults and children with hereditary Factor X deficiency for:<br> ◦Routine prophylaxis to reduce the frequency of bleeding episodes<br> ◦On-demand treatment and control of bleeding episodes<br> ◦Perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency<br>
Open in openFDA / FDA.gov